{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T10:19:12Z","timestamp":1700043552985},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,11,17]],"date-time":"2006-11-17T00:00:00Z","timestamp":1163721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2006,11,28]]},"DOI":"10.1007\/s11096-006-9050-6","type":"journal-article","created":{"date-parts":[[2006,11,16]],"date-time":"2006-11-16T13:20:35Z","timestamp":1163683235000},"page":"309-317","source":"Crossref","is-referenced-by-count":2,"title":["Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS"],"prefix":"10.1007","volume":"28","author":[{"given":"Steven","family":"Simoens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Coster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Ruyck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Stutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Laekeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,11,17]]},"reference":[{"key":"9050_CR1","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","volume":"160","author":"S Hernandez-Diaz","year":"2000","unstructured":"Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093\u20139.","journal-title":"Arch Intern Med"},{"key":"9050_CR2","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"MM Wolfe","year":"1999","unstructured":"Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888\u201399.","journal-title":"N Engl J Med"},{"key":"9050_CR3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et\u00a0al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520\u20138.","journal-title":"New Engl J Med"},{"key":"9050_CR4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"F Silverstein","year":"2000","unstructured":"Silverstein F, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et\u00a0al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 2000;284:1247\u201355.","journal-title":"J Am Med Assoc"},{"key":"9050_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. Br Med J 2002;325:619.","journal-title":"Br Med J"},{"key":"9050_CR6","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644\u201365.","journal-title":"Arthritis Res Ther"},{"key":"9050_CR7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/014107680609900315","volume":"99","author":"B Caldwell","year":"2006","unstructured":"Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006;99:132\u201340.","journal-title":"J R Soc Med"},{"key":"9050_CR8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.332.7546.895","volume":"332","author":"HE Vonkeman","year":"2006","unstructured":"Vonkeman HE, Brouwers JRBJ, van de Laar MAFJ. Understanding the NSAID related risk of vascular events. Br Med J 2006;332:895\u20138.","journal-title":"Br Med J"},{"key":"9050_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0091270005278202","volume":"45","author":"PA Konstantinopoulos","year":"2005","unstructured":"Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005;45:742\u201350.","journal-title":"J Clin Pharmacol"},{"key":"9050_CR10","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","volume":"364","author":"P J\u00fcni","year":"2004","unstructured":"J\u00fcni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021\u20139.","journal-title":"Lancet"},{"key":"9050_CR11","unstructured":"European Medicines Agency. European Medicines Agency announces regulatory action on COX-2 inhibitors. http:\/\/www.emea.eu.int (10 May 2006)."},{"key":"9050_CR12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780400816","volume":"40","author":"SF Lanes","year":"1997","unstructured":"Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, et\u00a0al. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum 1997;40:1475\u201381.","journal-title":"Arthritis Rheum"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-006-9050-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9050-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:51:29Z","timestamp":1559368289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-006-9050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,17]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11,28]]}},"alternative-id":["9050"],"URL":"https:\/\/doi.org\/10.1007\/s11096-006-9050-6","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,17]]}}}